Improved values regarding Acquired von Willebrand syndrome in patients with HeartMate III compared to HeartMate II
B. Zieger (Freiburg, Germany)

Blood clotting supports glioma invasion and colonization
J. Pilch (Homburg, Germany)

Reconstituted whole blood using fresh frozen plasma versus coagulation factors concentrates: an in vitro study
G. E. Iapichino (Wien, Austria)

Hemostatic potential of reconstituted whole blood using fresh frozen plasma versus increasing concentration of lyoplasma
G. E. Iapichino (Wien, Austria)

Trend in Hospital Cases of Acquired Hemophilia A (AHA) 2010 - 2014 in Germany
S. Wahler (Hamburg, Germany)

Procoagulant microparticles and nanoparticles from whole blood reconstituted with age-different blood components.
M. Ponschab (Vienna, Austria)

Longitudinal analyses of microparticle-associated tissue factor activity and venous thromboembolism (VTE) in cancer patients
E.-M. Reitter (Wien, Austria)

Thrombin formation capacity in patients with two different left-ventricular assist devices and after heart transplantation
A. Schlagenhauf (Graz, Austria)

Chronic disseminated intravascular coagulation in a patient with antiphospholipid antibodies and acquired protein S deficiency
C. Dicke (Hamburg, Germany)
Successful inhibitor eradication with ofatumumab in a patient with acquired hemophilia A
R. Fischer (Giessen, Germany)

Is a too low Plasminogen Level in the Plasma of Kidney Transplant Recipients the Reason of irreversible Rejection Reactions?
H. E. Karges (Marburg, Germany)

Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on chronic hemodialysis: results of the VIVALDI study
O. Königsbrügge (Vienna, Austria)

Dual mechanical assistance with veno-arterial extracorporeal membrane oxygenation and percutaneous continuous-flow device: double trouble for von Willebrand factor
S. Susen (Lille, France)

Direct oral thrombin inhibitor dabigatran etexilate is able to controle chronic disseminated intravasal coagulation: a case report
W. Korte (St. Gallen, Switzerland)

Management of epidural bleeding in a patient with acquired hemophilia A masked by phenprocoumon therapy
M. Alrifai (Giessen, Germany)

Poster, Foyer 2. OG
Antithrombotic treatment

How to assess in vivo anticoagulant effect of Rivaroxaban
D. Bertaggia Calderara (Lausanne, Switzerland)

Differential effects of novel anticoagulants: fXa versus fIIa inhibition on coagulation and inflammation
S. Nazir (Magdeburg, Germany)

Single-center experience with thrombolysis in high- and intermediate-risk pulmonary embolism
N. Herr (Freiburg, Germany)
Real Life Efficacy and Safety of Edoxaban for Stroke Prevention in Atrial Fibrillation – Results of the Prospective NOAC Registry (NCT01588119)
L. Tittl (Dresden, Germany)

Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians
S. Barco (Mainz, Germany)

CONKO-011: Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III study
M. Sinn (Berlin, Germany)

Long-term clinical outcomes of patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists: A prospective, multicenter cohort study of elderly patients with venous thromboemb
M. Nagler (Bern, Switzerland)

Clinical Observations on potential interactions of phenprocoumon, colchicine and Rivaroxaban in a patient with compound homozygosity for FV Leiden and Familial Mediterranean Fever (FMF, M680)
L. Graf (St. Gallen, Switzerland)

Poster, Foyer 2. OG
Arterial thrombosis

Activation of neutrophils - but not endothelial cells - is regulated by serotonin during myocardial reperfusion injury
M. Mauler (Freiburg, Germany)

Protein C and factor X activities from patients with ischemic stroke and type II diabetes mellitus.
O. Kravchenko (Kyiv, Ukraine)

Inhibition of Coagulation Factor Xa Attenuates Myocardial Ischemia Reperfusion Injury in Mice
J. J. Posma (Wijnandsrade, The Netherlands)

Idiopathic catastrophic thrombosis with happy end - a case report
J. Heid (Heidelberg, Germany)
The molecular etiology and pathophysiology of platelet-mediated aspirin responsive erythromelalgia and microvascular thrombosis in JAK2, CALR and MPL mutated thrombocythemia
J. J. Michiels (Rotterdam, The Netherlands)

Effect of alpha-2 plasmin inhibitor p.Arg6Trp polymorphism and antigen level on the risk of myocardial infarction in young patients
E. Katona (Debrecen, Hungary)

**5:15 pm**

**Poster, Foyer 2. OG**

Bleedings disorders, coagulation and fibrinolytic factors

Amidolytic thrombin activity under the ischemic stroke peptide pool influence
T. Katrii (Kyiv, Ukraine)

What Haemophilia Patients Expect from the New Extended Half-Life (EHL) Products and Their Willingness to Switch - Results from the DACH Region
S. von Mackensen (Hamburg, Germany)

Monitoring of perioperative factor VIII treatment in a remote hospital by electronic diary smart medicationTM
W. Mondorf (Frankfurt am Main, Germany)

An Asp94Gly missense mutation in GP1BB causes severe Bernard-Soulier syndrome in an Iraqi family
D. Boeckelmann (Freiburg, Germany)

Impact of Maintaining Higher FVIII Trough Levels with BAX 855: Rationale and Design of the PROPEL Study
H.-Y. Lee (Zurich, Switzerland)

Nonacog beta pegol in adult and paediatric patients: pooled data from the paradigm^TM clinical programme
J. Oldenburg (Bonn, Germany)

Introduction of a guideline for the treatment of synovitis in patients with hemophilia
B. Habermann (Mainz, Germany)
Challenges in immune tolerance induction in an adult patient with non-severe haemophilia A.
P. Kuta (Erlangen, Germany)

Prevalence of overweight and obesity in children, adolescents and young adults with severe hemophilia A – results of 3 German pediatric hemophilia treatment centers
M. Olivieri (Munich, Germany)

Pharmacokinetic results of two studies with a novel fibrinogen concentrate in subjects with afibrinogenaemia.
W. Stevens (Les Ulis, France)

Pitfalls in carrier testing of Haemophilia A
B. Preisler (Bonn, Germany)

Long-term use of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B
S. Halimeh (Duisberg, Germany)

Resolution of target joints during once-weekly prophylaxis with rIX-FP in patients with hemophilia B
H. J. Laws (Dusseldorf, Germany)

Epidemiological insights about Hemophilia B by analysis of German hospital quality reports
S. Wahler (Hamburg, Germany)

rVIII-SingleChain: Results of a Phase III PK, efficacy and safety study in children less than 12 years of age with severe hemophilia A
I. Pabinger (Vienna, Austria)

Efficacy and safety of a VWF/FVIII concentrate in surgical procedures – results from the ongoing study Wilate-STATE
S. Halimeh (Duisburg, Germany)

Combined congenital deficiency of coagulation factors VII and X in two siblings with heterozygous factor V Leiden mutation (R506Q)
K. Heidinger (Gießen, Germany)
Efficacy and safety of rVIII-SingleChain in 21 major surgeries
J. Oldenburg (Bonn, Germany)

A preliminary study to find novel interaction partners for the coagulation Factor XIII (FXIII) B subunit free form
S. Singh (Bonn, Germany)

The coagulation Factor XIII (FXIII) A subunit activation peptide directs the evolution of FXIIIA as a proteolytically activated dimeric molecule
A. Biswas (Bonn, Germany)

Determining the causality of heterozygous missense mutations detected in F13A1 and F13B genes and reported from patients with mild coagulation Factor XIII (FXIII) deficiency
A. Biswas (Bonn, Germany)

Annual Bleeding vs. Factor VIII/IX consumption – comparison of result in 2014 and 2015 according to electronic diary smart-medicationTM
R. Fischer (Giessen, Deutschland)

Comparison of data security of the electronic patient diary smart medication™ with manual documentation in a paper diary
A. Roesch (Dreieich, Germany)

The regulatory profile of the 5´ untranslated region of F13A1 gene of coagulation Factor XIII (FXIII) A subunit
M. A. Jamil (Bonn, Germany)

Long-term Immunogenicity, Safety and Efficacy of Human-cl rhFVIII in Previously Treated Children with Severe Haemophilia A
J. Bichler (Lachen, Switzerland)

Individualized prophylaxis with Nuwiq® (Human-cl rhFVIII) in adult PTPs with severe haemophilia A
J. Bichler (Lachen, Switzerland)

Efficacy and safety of Nuwiq® in clinical trials with previously treated patients with severe haemophilia A
R. Klamroth (Berlin, Germany)
Interim bleeding data of 522 hemophilia A patients from the international AHEAD Study after 3 years of observation
K. Steinitz-Trost (Vienna, Austria)

Feiba Global Outcome Study (FEIBA-GO): first demographic data from a real world study on FEIBA in patients with inhibitors
K. Steinitz-Trost (Vienna, Austria)

Inhibitor Development in Previously Untreated Patients with Severe Haemophilia A Treated with Human-cl rhFVIII, a New Generation Recombinant FVIII of Human Origin
A. Russo (Mainz, Germany)

FSAP and altered fibrin clot structure: Is there a link to FXIII?
M. Etscheid (Langen, Germany)

Autologous Serum Infusion induces no Thrombin Formation but Generation of Activated Protein C
C. Berens (Bonn, Germany)

Treatment of acquired hemophilia A with recombinant porcine FVIII in Germany
C. Hart (Regensburg, Germany)

Pulmonary embolism in a patient with severe factor VII deficiency after femoral neck fracture despite thromboprophylaxis with low-molecular-weight heparin
K. Holstein (Hamburg, Germany)

Genetic Therapy for Haemophilia: What’s new?
M.-K. Holz (Essen, Germany)

In-vitro analysis of siRNA based inhibition of function of activated protein C (APC): Towards an alternative therapeutic option for hemophilia.
D. Mirgal (Mumbai, India)

Novel insights in the molecular etiology of recessive von Willebrand Disease 2N due to D’D3 Factor VIII-binding site mutations of von Willebrand factor
J. J. Michiels (Rotterdam, The Netherlands)
Comparison of biomarkers and immunological parameters between haemophilia patients, rheumatoid arthritis patients, and control subjects
R. Toenges (Frankfurt am Main, Germany)

Protein S and Purpura Fulminans: What’s new?
R. Prince (Bern, Switzerland)

Successful factor VIII re-exposure after long-term aPCC prophylaxis in two hemophilia A patients with inhibitors
C. Königs (Frankfurt am Main, Germany)

rVIII-SingleChain in hemophilia A patients: A population pharmacokinetic model
A. Veldman (Marburg, Germany)

Poster, Foyer 2. OG
Laboratory tests

Protein Z - Does its analyzation make any clinical sense?
G. Kappert (Duisburg, Germany)

Platelet aggregation testing on a routine coagulation analyzer
W. Miesbach (Frankfurt am Main, Germany)

Unambiguous and sensitive measurement of active coagulation proteases
A. Weber (Vienna, Austria)

Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII product
A. Weber (Vienna, Austria)

Quantification of TAFI in human plasma by LC-MS/MS
M. Rauh (Erlangen, Germany)
Diagnostic challenges of von Willebrand disease
S. Schneppenheim (Hamburg, Germany)

A Rapid and Simple Assay for the determination of ADAMTS-13 Activity
M. Griffiths (Vienna, Austria)

Activation and Inactivation of rVIII-SingleChain
C. Horn (Marburg, Germany)

Evaluation and clinical validation of a chromogenic FIX assay for reliable post infusion measurements of recombinant and next generation factor IX products
J. Müller (Bonn, Germany)

TechnoZym® ADAMTS-13 activity assay for determination of inhibitory antibodies against ADAMTS-13
L. Wagner (Vienna, Austria)

Measuring Direct Oral Anticoagulants in standardized fully automated Thrombin Generation on Ceveron® alpha
L. Wagner (Vienna, Austria)

Evaluation of DOAC Interferences on Technoclot® PT Owren
L. Rosenmayr (Vienna, Austria)

Difficulties in diagnosing antiphospholipid syndrome in patients undergoing DOAC therapy
T. Flieder (Bad Oeynhausen, Germany)

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in the one-stage assay
A. Veldman (Marburg, Germany)

Development and evaluation of a novel FVIII domain-specific immunoassay for characterization of anti-FVIII antibodies
B. Pezeshkpoor (Bonn, Germany)
rVIII-SingleChain plasma activity can be measured using both the one-stage and the chromogenic substrate assay: Results from an international field study
A. Veldman (Marburg, Germany)

Platelet-dependent von Willebrand factor activity - an important constituent of the diagnostic repository to classify von Willebrand syndrome.
O. Tiebel (Dresden, Germany)

Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: comparison of diagnostic accuracy, reproducibility, and costs in clinical practice
A. Bankova (Lucerne, Switzerland)

Is platelet aggregation testing dependent on fibrinogen level?
L. Graf (St. Gallen, Switzerland)

Replacing the aPTT for monitoring of unfractionated heparin with the Prothrombinase induced Clotting Time (PiCT) – significant influence on dosing.
W. Korte (St. Gallen, Switzerland)

Clauss Fibrinogen Assay obviously underestimates Fibrinogen level not confirmed in Thromboelastometry – A Case Report
T. Lang (Hohne, Germany)

A Flow cytometer-based platelet aggregation assay permits platelet function testing in small blood volumes
S. Liedtke (Greifswald, Germany)

Genetic heterogeneity in patients with von Willebrand disease type I: a regional study from Northeast Germany
M. Steiner (Rostock, Germany)

Comparison of factor VIII assays using physiological triggers
G. J. Praefcke (Langen, Germany)

Poster, Foyer 2. OG
Pediatric and neonatal thrombosis and hemostasis
The „German Pediatric Hemophilia Research Database“ (GEPhARD) – a project of the `Standing Committee Pediatrics of the Society for Thrombosis and Hemostasis Research´ to improve the quality
C. Bidlingmaier (Munich, Germany)

Acquired von Willebrand Disease in infants with aortopulmonary shunt
G. Wiegand (Tuebingen, Germany)

Late onset of thrombosis in siblings with homozygous protein C deficiency
C. Wermes (Hannover, Germany)

Adolescent male suffering from thrombosis is not uncommon
I. Wieland (Hannover, Germany)

Thrombotic events in the neonatal period – a case series of common manifestations
M. Rohde (Gießen, Germany)

Anterior spinal artery syndrome in pediatric patients: diagnostic and therapy
A. M. Cseh (Freiburg, Germany)

Systemic Mast Cell Activation Disease during Adolescence and Heparin Levels in Blood Plasma
M. Vysniauskaite* (Bonn, Germany)

Poster, Foyer 2. OG
Platelets - Physiology and Disorders of platelet number and function

The special role of anti-Adamts13-IgA in acquired TTP: Production induced by infectious microorganisms?
I. Scharrer (Mainz, Germany)

Immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies in a cohort of 47 patients with acquired thrombotic thrombocytopenic purpura
G. Sinkovits (Budapest, Hungary)
Phosphorylation of the protein phosphatase 2A inhibitor alpha-endosulfine (ENSA) at two distinct sites, serine 67 and serine 109, in human platelets
E. Walter (Mainz, Germany)

Variable linkage with platelet functions of genetic mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficiencies
M. Nagy (Maastricht, The Netherlands)

Intra- and intercellular fate of iron oxide nanoparticles in platelets
K. Aurich (Greifswald, Germany)

Frequency and analysis of hospital cases of heparin induced thrombocytopenia type 2 (HIT 2) in Germany
S. Wahler (Hamburg, Germany)

Phenotyping platelets from patients with inherited platelet disorders by immunofluorescence microscopy
K. Althaus (Greifswald, Germany)

Initiation of a prospective observational cohort study of patients with acquired thrombotic thrombocytopenic purpura (TTP)
T. Falter (Mainz, Germany)

Evaluation of platelet parameters in pediatric thrombocytopenic patients
R. Knöfler (Dresden, Germany)

Whole Blood Flow Cytometry Measurements and ex vivo Platelet Activation in critically-ill neonates
M. Topalidou (Thessaloniki, Greece)

The power of large platelets: Comprehensive functional characterization of large and small platelets from healthy volunteers.
S. Handtke (Greifswald, Germany)

Annexin A7 (ANX7) regulates collagen-dependent platelet activation and Ca2+ signaling
S. Geue (Tübingen, Germany)
Evaluation of platelet activation after electric cardioversion
J. Gaugler (Graz, Austria)

Platelet dense granule production and dense granule release defects in pediatric patients with storage pool disorder
J. Eilenberger (Würzburg, Germany)

Practical limitations of diagnostic algorithms in Heparin induced thrombocytopenia: A case report.
S. Nowak-Harnau (Tübingen, Germany)

Supra-normal closure time caused by recombinant von Willebrand factor in PFA
T. Kragh (Munich, Germany)

Prophylactic Plasma Treatment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura
Z. Cermakova (Ostrava, Czech Republic)

Poster, Foyer 2. OG
Vascular wall biology and disorders

CLIC1 supports mechanisms related to thrombosis and vascular repair
L. M. Knowles (Homburg, Germany)

Activated protein C protects against accelerated atherosclerosis in diabetes by restricting p66shc expression in macrophages
K. Shahzad (Magdeburg, Germany)

Autophagy status in factor VIII secreting endothelial cells
M. A. Jamil (Bonn, Germany)

Analysis of proteolytic von Willebrand factor (VWF) fragments in patients with VWF-related diseases
J. Irle (Mainz, Germany)
In patients with uncontrolled arterial hypertension platelets and coagulation factor XI are responsible of modifications of thrombin generation.
J. Lagrange (Mainz, Germany)

Investigating the interconnection between complement and coagulation in xenotransplantation
R. Sfriso (Bern, Switzerland)

Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension
S. Kossmann (Mainz, Germany)

Collagen V alpha 2 as a direct target of miR-143 in arteriogenesis
T. Hammerschick (Giessen, Germany)

Molecular genetic investigations and demonstration of founder effect in Osler-Rendu-Weber disease
R. Gindele (Debrecen, Hungary)

Poster, Foyer 2. OG
Venous thrombosis

Clinical relevance of marginal low Protein S
P. Lodemann (Berlin, Germany)

Characterisation of previously unknown protein C gene variants
S. Körber (Frankfurt am Main, Germany)

GE-CAT - German Evaluation of Cancer associated Thrombosis A prospective register trial for patients with hematological and oncological diseases and venous thromboembolism in Berlin
A. Jühling (Berlin, Germany)

Study of fibrinolytic parameters in Indian patients with venous thrombosis
A. Prabhudesai (Mumbai, India)
Characterization of Antithrombin variants in thrombotic patients with normal and reduced activity.
R. Deshpande (Mumbai, India)

Application of massive parallel sequencing searching for rare genetic variants associated with thrombophilia - implementation to clinical practice.
P. Vrtel (Olomouc, Czech Rep)

Advances in diagnosis, classification and management of lower extremity deep vein thrombosis (DVT), prevention of DVT recurrence and the post-thrombotic syndrome: personal experiences and a
J. J. Michiels (Rotterdam, The Netherlands)

The role of an endothelial specific g-protein coupled receptor in thrombosis
L. Gottlob (Solna, Sweden)

5:15 pm  
Poster, Foyer 2. OG
Women issues in thrombosis and hemostasis

Angiogenesis in a porcine von Willebrand disease model
M. von Depka (Hannover, Germany)

Successful pregnancy in patient with homozygous sickle cell disease and prior pulmonary embolism – a case report
J. Notter (Basel, Switzerland)

Highly procoagulant extracellular vesicles in amniotic fluid
J. Thaler (Wien, Austria)

Dead fetus syndrome (DFS) in 2017 - a no more existing entity? From individual patients to pathophysiological insights
F. Bergmann (Hannover, Germany)

Risk of pregnancy-associated recurrent venous thromboembolism (VTE) in women with a history of first venous thrombosis
A. Gerhardt (Ulm, Germany)
Comparison of two laboratory methods for thrombin generation in pregnancy with high risk for thrombosis
M. Schwethelm (Basel, Switzerland)

Bernard Soulier syndrome in pregnancy and delivery – a case report
K. Liebscher (Leipzig, Germany)

Successful pregnancy outcome in a case of JAK2 positive Essential Thrombocytemia after treatment with Peginterferon alpha-2b
M.-V. Teleanu (Ulm, Germany)

Poster, Foyer 2. OG
Innovation and Novelty

Development and application of methods for the selective measurement of the human single amino exchange variant factor IX Padua
A. Weber (Vienna, Austria)

Fucoidans Inhibit Cellular Responses to the Chemokine IL-8 and the Anaphylatoxin C5a Better than Heparin
S. Alban (Kiel, Germany)

P2Y6 depletion enhances metabolic activity and ameliorates outcome of high fat diet induced obesity in mice
J. Merz (Freiburg, Germany)